Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Corteva, Inc. reported financial results for the quarter ended December 31, 2019 and the full year 2019.
Kezar Life Sciences, Inc. has announced the pricing of an underwritten public offering of 16,115,385 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 2,884,615 shares of its common stock at an exercise price of $0.001 per share.
Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, has announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a price to the public of $17.00 per share.
Three months after Sandoz announced it would acquire the Japanese business of Aspen Global Incorporated, a subsidiary of Aspen Pharmacare Holdings for $330 million, the deal has been completed.
The Company and its wholly owned subsidiary, Motif BioSciences Inc., have entered into a loan Amendment and Release agreement with Hercules Capital Inc., the senior secured lender to Motif Inc, regarding certain actions which fully satisfy the conditions attached to the Company’s previously announced agreement in principle with Hercules
CYNBIOME receives funding under Investments for the Future Program (PiA), supplemented by €3M ($3.3M) of Cynbiose’s own funds
The merged companies will operate under the name Histogen and trade on the Nasdaq Capital Market under a new ticker symbol.
PDC*line Pharma announces the completion of its Series B round of financing.
The company announced it had rejected the bid, saying that it “significantly undervalues Sorrento and is not in the best interest of the Company’s stockholders.”
As AbbVie and Allergan near completion of the $63 billion merger, the two companies are shedding some assets in order to meet demands of regulators over concerns of a monopoly.